Inogen (NASDAQ:INGN) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Posted by Geri Gentry on Aug 8th, 2026

Inogen (NASDAQ:INGN – Get Free Report) issued its earnings results on Thursday. The medical technology company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01, FiscalAI reports. The business had revenue of $95.08 million for the quarter, compared to the consensus estimate of $95.23 million. Inogen had a negative net margin of 6.94% and a negative return on equity of 12.89%.

Here are the key takeaways from Inogen’s conference call:

Full-year revenue guidance was reduced to $355 million–$361 million from $366 million–$373 million, reflecting ongoing U.S. direct-channel pressure and the timing of international distributor inventory purchases. Management expects third-quarter revenue to be roughly flat year over year.
International sales increased 15% year over year to $41.3 million, marking the tenth consecutive quarter of double-digit growth. Inogen cited expansion in Eastern Europe, Latin America, and Canada as longer-term growth drivers, although some distributor purchases may be delayed in the second half.
Profitability improved, with adjusted EBITDA rising 15% year over year to $2.4 million and adjusted gross margin expanding to 45.6%. The company raised full-year adjusted EBITDA guidance to approximately $4 million, up 48% from 2025.
New products are gaining traction: Boxy has shipped more than 5,000 units, while Aurora CPAP mask customer accounts more than doubled sequentially. Together, Boxy and Aurora contributed slightly more than 100 basis points of second-quarter growth and are expected to accelerate in the second half.
U.S. POC unit volume grew at a high-single-digit rate, but U.S. revenue fell 2% and rental revenue declined 12% as HMEs increasingly prescribe portable concentrators at the start of therapy, reducing the traditional rental funnel. Management is reviewing options to improve the rental business while investing in B2B sales execution.

Inogen Price Performance

Inogen stock traded down $0.44 during midday trading on Friday, hitting $6.05. 599,111 shares of the company were exchanged, compared to its average volume of 222,691. The company has a market cap of $163.83 million, a PE ratio of -6.72 and a beta of 1.55. Inogen has a fifty-two week low of $5.34 and a fifty-two week high of $9.13. The company’s fifty day moving average price is $6.46 and its 200-day moving average price is $6.38.

Insider Activity

In other news, EVP Boyer Jennifer M. Yi sold 10,938 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $6.60, for a total value of $72,190.80. Following the completion of the transaction, the executive vice president directly owned 5,039 shares in the company, valued at approximately $33,257.40. This represents a 68.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in INGN. Kent Lake PR LLC increased its holdings in Inogen by 5.7% in the second quarter. Kent Lake PR LLC now owns 1,061,294 shares of the medical technology company’s stock valued at $7,461,000 after buying an additional 57,700 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in shares of Inogen by 0.8% in the 2nd quarter. Ameriprise Financial Inc. now owns 881,100 shares of the medical technology company’s stock worth $6,194,000 after acquiring an additional 6,573 shares during the period. Armistice Capital LLC raised its holdings in shares of Inogen by 30.1% during the third quarter. Armistice Capital LLC now owns 864,000 shares of the medical technology company’s stock valued at $7,059,000 after buying an additional 200,000 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Inogen by 7.9% in the second quarter. Geode Capital Management LLC now owns 615,279 shares of the medical technology company’s stock worth $4,326,000 after purchasing an additional 44,860 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Inogen by 37.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 589,273 shares of the medical technology company’s stock valued at $3,960,000 after buying an additional 160,960 shares during the period. 89.94% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Inogen in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Inogen presently has an average rating of “Moderate Buy”.

Check Out Our Latest Research Report on Inogen

About Inogen

(Get Free Report)

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.